Home » Stocks » LABP

Landos Biopharma, Inc. (LABP)

Landos Biopharma will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Market Cap n/a
Revenue (ttm) n/a
Net Income (ttm) -22.31M
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

News

Hide News
NASDAQ - 5 days ago

Landos Biopharma, a Phase 2 biotech developing oral small molecule therapies for autoimmune diseases, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.

SEC - 5 days ago

Landos Biopharma, Inc. has filed to go public with an IPO on the NASDAQ.

About LABP

Landos Biopharma is a clinical-stage biopharmaceutical company developing novel, disease-specific oral therapeutic candidates designed to address the therapeutic gap in the current treatment paradigm for autoimmune diseases.. We believe the therapeutics we discover and develop, if approved, will have a significant impact on the quality of life of patients suffering from autoimmune diseases. While great strides have been made, existing approaches continue to leave patient needs unmet, due in part to significant safety concerns. Our core experti... [Read more...]

Industry
Pharmaceutical Preparations
IPO Date
Pending
CEO
Josep Bassaganya-Riera
Employees
33
Stock Exchange
NASDAQ
Ticker Symbol
LABP
Full Company Profile

Financial Performance

Financial Statements